세포 치료 시장 기회 및 예측(2017-2031년) : 치료 유형별, 세포 유형별, 제품 유형별, 용도별, 최종사용자별, 지역별

Global cell therapy market size was valued at USD 4.67 billion in 2023, expected to reach USD 12.93 billion in 2031, with a CAGR of 13.56% for the forecast period between 2024 and 2031. Several factors propel the global cell therapy market, creating an exciting and high-potential environment. Key drivers include the rising prevalence of chronic diseases, increasing investments in research and development, continuous advancements in cell therapy technologies, a supportive regulatory environment, collaborative partnerships, and growing applications. A prominent force behind the growing demand is the increasing prevalence of chronic diseases worldwide. As these conditions become more prevalent, there is an increasing demand for innovative and effective treatments, positioning cell therapy as a promising solution.

Pharmaceutical companies and research institutions are investing significant amounts in exploring the vast potential of cell therapies. This financial commitment fosters groundbreaking discoveries and accelerates the development of novel treatments. Advancements in cell therapy technologies are further contributing to this dynamic landscape. Breakthrough technologies such as CRISPR gene editing are enhancing the precision and efficacy of cell therapies, opening new possibilities for therapeutic interventions across various medical domains in global cell therapy market. A supportive regulatory environment acts as a catalyst, streamlining approval processes and encouraging companies to invest in the development of cell-based treatments, boosting the growth of the global cell therapy market. Collaborative partnerships between pharmaceutical/biotech firms, and academic institutions leverage collective strengths, fostering innovation and expediting the commercialization of promising therapies. As cell therapy applications continue to broaden from oncology to neurodegenerative diseases, the global awareness and acceptance of these innovative treatments are on the rise.

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a significant catalyst for the global cell therapy market. As the population aged 50 and above faces a staggering increase in the incidence of at least one chronic disease, the numbers are projected to surge by 99.5%, reaching 142.66 million by 2050 from 71.522 million in 2020. The demographic shift signifies an urgent need for advanced and effective therapeutic interventions, with cell therapy emerging as a promising solution. Moreover, the projection of a 91.16% increase in individuals with multimorbidity-from 7.8304 million in 2020 to 14.968 million in 2050, highlights the complexity of health challenges an aging population faces. In response to the growing health burden, the demand for innovative cell therapies is rising, positioning the market to address the evolving healthcare landscape and offer targeted solutions for chronic disease management.

Growing Investments for Developing Modern Cell Therapy Solutions

Leading companies are investing substantially in cell therapy by establishing state-of-the-art manufacturing facilities. The initiative reflects their confidence in cell therapies' potential and is a significant driver for the global cell therapy market. Significant investments in advanced production facilities enable increasing production capacity and scalability, resulting in a more efficient and widespread delivery of cell-based treatments. The proactive approach by major industry players fosters innovation and contributes to the overall growth and maturity of the global cell therapy market, solidifying their position as a transformative force in healthcare.

For instance, in October 2023, Bayer AG revealed its inaugural cell therapy launch facility in Berkeley, California, marking a pivotal step in their global initiative to provide cell therapies to patients. The USD 250 million, 100,000-square-foot facility is designed to meet the demand for materials in late-stage clinical trials and the potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy under assessment for Parkinson's disease treatment. The establishment of the cutting-edge facility underscores Bayer's commitment to advancing cell therapies on a global scale and signifies a significant investment in the future of innovative medical solutions.

Government Initiatives

Governments around the globe are collaborating with major companies to stimulate the growth of the global cell therapy market. These partnerships aim to leverage governmental support and expertise to advance research, development, and accessibility of cell therapies. By fostering such collaborations, policymakers seek to create a conducive environment for innovation, accelerate regulatory approvals, and ensure widespread adoption of these advanced medical interventions. The synergy between governments and key industry players reflects a shared commitment to realize the full potential of cell therapies in revolutionizing healthcare and addressing challenges on a global scale.

In September 2023, the United States government unveiled new measures as part of the Cancer Moonshot Initiative, a focal point in the battle against cancer. The initiative was led by President through the collaborative entity "CancerX," aiming to reduce the U.S. cancer death rate by 50% before 2047. The initiative includes prominent pharmaceutical companies and their partnership with digital healthcare solution providers such as Amazon and Intel. The Moffitt Cancer Center in Florida and the Digital Medicine Society (DiMe), a global non-profit of digital medicine experts, lead the effort.

Growing Demand for T-Cell Therapy

The global cell therapy market is witnessing a growing demand for T-cell therapy. The innovative approach has gained prominence due to its remarkable success in treating certain cancers, especially hematologic malignancies. As clinical trials demonstrate its efficacy and safety, the demand for T-cell therapy is increasing. Patients, healthcare providers, and pharmaceutical companies recognize its potential to revolutionize cancer treatment by leveraging the body's immune system. The increasing demand is propelling research, development, and investment in T-cell therapies, contributing to the dynamic growth of global cell therapy market.

In March 2023, Thermo Fisher Scientific and Arsenal Biosciences, Inc., American companies, announced their strategic partnership to advance the manufacturing processes for novel cancer treatments. The collaboration emphasizes research and process development to establish a robust manufacturing framework for their cutting-edge, programmable autologous T cells designed for cancer treatment.

Future Market Scenario

The global cell therapy market is poised for a promising future, driven by a convergence of factors highlighting its potential to revolutionize healthcare. Advancements in cell therapy technologies, including precision-enhancing techniques like CRISPR gene editing, are increasing the efficacy and scope of treatments. The rising prevalence of chronic diseases, such as cancer and autoimmune disorders, create a compelling need for innovative therapeutic solutions, positioning cell therapy at the forefront of medical breakthroughs. Collaborative partnerships between pharmaceutical companies, biotech firms, and academic institutions are accelerating research and development efforts, fostering a dynamic environment of innovation. Supportive regulatory frameworks and increasing stakeholder awareness contribute towards a favorable landscape for the market's growth. With expanding applications across diverse medical domains and a global commitment to addressing unmet healthcare needs, the cell therapy market is poised to play a pivotal role in shaping the future of healthcare.

Key Players Landscape and Outlook

Numerous major companies are actively forming collaborations in the global cell therapy market. These strategic partnerships facilitate the pooling of resources, expertise, and technologies to drive innovation and expedite the development of advanced cell-based therapies. By joining forces, these companies enhance their capabilities in research, clinical trials, and manufacturing processes, ultimately contributing to the evolution and expansion of the cell therapy market.

For instance, in August 2023, Astellas Pharma Inc. and Poseida Therapeutics, Inc. unveiled a strategic investment to bolster Poseida's pioneering efforts in redefining cancer cell therapy. In the financial arrangement, Astellas is set to invest a total of USD 50 million, comprising a USD 25 million acquisition of 8,333,333 shares of Poseida's common stock (representing around 8.8% of the total outstanding common stock) at USD 3.00 per share through a private placement. Additionally, a one-time payment of USD 25 million secures Astellas an exclusive negotiation and first refusal right to license Poseida's clinical stage program, P-MUC1C-ALLO1. The program involves the development of an allogeneic CAR-T cell therapy targeting multiple solid tumor indications.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Cell Therapy Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. Value
  • 4.1.2. Volume
• 4.2. By Therapy Types
  • 4.2.1. Allogenic Therapies
  • 4.2.2. Autologous Therapies
• 4.3. By Cell Type
  • 4.3.1. Stem Cell
  • 4.3.2. Non-Stem Cell
• 4.4. By Product
  • 4.4.1. Media, Sera, and Reagents
  • 4.4.2. Cell Engineering Products
  • 4.4.3. Cell Culture Vessels
  • 4.4.4. Cell Therapy Equipment
  • 4.4.5. System and Software
  • 4.4.6. Other Products
• 4.5. By Application
  • 4.5.1. Cardiovascular
  • 4.5.2. Musculoskeletal
  • 4.5.3. Oncology
  • 4.5.4. Dermatology
  • 4.5.5. Others
• 4.6. By End-users
  • 4.6.1. Hospitals and Clinics
  • 4.6.2. Biopharmaceutical and Biotech Companies
  • 4.6.3. Academic and Research Institutes
  • 4.6.4. Others
• 4.7. By Region
  • 4.7.1. North America
  • 4.7.2. Europe
  • 4.7.3. South America
  • 4.7.4. Asia-Pacific
  • 4.7.5. Middle East and Africa
• 4.8. By Company Market Share (%), 2023

5. Global Cell Therapy Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. Value
    • 5.1.1.2. Volume
  • 5.1.2. By Therapy Types
    • 5.1.2.1. Allogenic Therapies
    • 5.1.2.2. Autologous Therapies
  • 5.1.3. By Cell Type
    • 5.1.3.1. Stem Cell
    • 5.1.3.2. Non-Stem Cell
  • 5.1.4. By Product
    • 5.1.4.1. Media, Sera, and Reagents
    • 5.1.4.2. Cell Engineering Products
    • 5.1.4.3. Cell Culture Vessels
    • 5.1.4.4. Cell Therapy Equipment
    • 5.1.4.5. System and Software
    • 5.1.4.6. Other Products
  • 5.1.5. By Application
    • 5.1.5.1. Cardiovascular
    • 5.1.5.2. Musculoskeletal
    • 5.1.5.3. Oncology
    • 5.1.5.4. Dermatology
    • 5.1.5.5. Others
  • 5.1.6. By End-users
    • 5.1.6.1. Hospitals and Clinics
    • 5.1.6.2. Biopharmaceutical and Biotech Companies
    • 5.1.6.3. Academic and Research Institutes
    • 5.1.6.4. Others
  • 5.1.7. United States*
    • 5.1.7.1. Market Size & Forecast
    • 5.1.7.1.1. Value
    • 5.1.7.1.2. Volume
    • 5.1.7.2. By Therapy Types
    • 5.1.7.2.1. Allogenic Therapies
    • 5.1.7.2.2. Autologous Therapies
    • 5.1.7.3. By Cell Type
    • 5.1.7.3.1. Stem Cell
    • 5.1.7.3.2. Non-Stem Cell
    • 5.1.7.4. By Product
    • 5.1.7.4.1. Media, Sera, and Reagents
    • 5.1.7.4.2. Cell Engineering Products
    • 5.1.7.4.3. Cell Culture Vessels
    • 5.1.7.4.4. Cell Therapy Equipment
    • 5.1.7.4.5. System and Software
    • 5.1.7.4.6. Other Products
    • 5.1.7.5. By Application
    • 5.1.7.5.1. Cardiovascular
    • 5.1.7.5.2. Musculoskeletal
    • 5.1.7.5.3. Oncology
    • 5.1.7.5.4. Dermatology
    • 5.1.7.5.5. Others
    • 5.1.7.6. By End-users
    • 5.1.7.6.1. Hospitals and Clinics
    • 5.1.7.6.2. Biopharmaceutical and Biotech Companies
    • 5.1.7.6.3. Academic and Research Institutes
    • 5.1.7.6.4. Others
  • 5.1.8. Canada
  • 5.1.9. Mexico

All segments will be provided for all regions and countries covered:

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. South America
  • 5.3.1. Brazil
  • 5.3.2. Argentina
• 5.4. Asia-Pacific
  • 5.4.1. India
  • 5.4.2. China
  • 5.4.3. Japan
  • 5.4.4. Australia
  • 5.4.5. Vietnam
  • 5.4.6. South Korea
  • 5.4.7. Indonesia
  • 5.4.8. Philippines
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Therapy Type
• 6.2. By Cell Type
• 6.3. By Product
• 6.4. By Application
• 6.5. By End-users
• 6.6. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Thermo Fisher Scientific Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Merck KGaA
• 13.3. AstraZeneca plc
• 13.4. Astellas Pharma Inc.
• 13.5. Danaher Corporation
• 13.6. Sanofi S.A.
• 13.7. Becton, Dickinson and Company
• 13.8. Lonza Group
• 13.9. Novartis AG
• 13.10. Fresenius Medical Care AG & Co. KGaA
• 13.11. Avantor, Inc.
• 13.12. Bio-Techne Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer